Zura Bio Limited Class A Ordinary Shares (ZURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $104.03M
Last updated: Nov 17, 2026 at 4:26 PM ET
Zura Bio Limited Class A Ordinary Shares (ZURA) Stock Chart
Zura Bio Limited Class A Ordinary Shares (ZURA) has a latest price of $1.03 on Nov 17, 2026, 86.1% below its 52-week high of $7.44. Its price fell 74.6% over the past 12 months. The month-end price fell 59.1% over the 5 years through Oct 2026, a compound annual decline of 16.4%.
Price Chart
From Sep 2021 to Oct 2026, its highest month-end close was $14.92 in Mar 2023 and its lowest $1.01 in May 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ZURA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ZURA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 82.3%, and over 6 months it fell 74.1%. The month-end price fell 14.0% over the 3 years through Oct 2026, a compound annual decline of 4.9%.
| Period | Change |
|---|---|
| 1 month | -72.8% |
| 3 months | -82.3% |
| 6 months | -74.1% |
| 12 months | -74.6% |
| 12 months, with dividends | -74.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -14.0% | -4.9% |
| 5 years | -59.1% | -16.4% |
Price by Year
Its best calendar year was 2025, when the price rose 109.6%, and its weakest was 2023, when it fell 54.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.04 | -22.9% |
| 2025 | $5.24 | +109.6% |
| 2024 | $2.50 | -46.5% |
| 2023 | $4.67 | -54.3% |
| 2022 | $10.21 | +3.4% |
Trading Range
The price is 72.8% below its 50-day average of $3.81 and 79.4% below its 200-day average of $5.03.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.03 | |
| 52-week high | $7.44 | -86.1% |
| 52-week low | $0.93 | +10.8% |
| 50-day average | $3.81 | -72.8% |
| 200-day average | $5.03 | -79.4% |
Price Risk
Over 3 years, its largest fall from a peak was 85.3%.
| Measure | Value |
|---|---|
| 1-year beta | 0.07 |
| Largest fall, 1 year | -85.3% |
| Largest fall, 3 years | -85.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ZURA
What is ZURA's 1-year price change?
Zura Bio Limited Class A Ordinary Shares's price fell 74.6% over the past 12 months. With dividends included, the 12-month total return was -74.6%.
What is ZURA's 5-year price change?
Zura Bio Limited Class A Ordinary Shares's month-end price fell 59.1% over the 5 years through Oct 2026, a compound annual decline of 16.4%. These figures leave out dividends.
What is ZURA's 52-week high and low?
Zura Bio Limited Class A Ordinary Shares's 52-week high is $7.44 and its 52-week low is $0.93. Its latest price of $1.03 on Nov 17, 2026 is 86.1% below the high.
What is ZURA's beta?
Zura Bio Limited Class A Ordinary Shares's 1-year beta against the S&P 500 is 0.07, so its price has shown little link to the market's moves over the past year. Its largest fall from a peak over the past year was 85.3%.
Is the ZURA chart free?
Yes. Advanced Charting for ZURA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ZURA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors